CrisprBits

Developing affordable CRISPR-based diagnostics, gene-editing tools, and therapeutics for human and planetary well-being.

Website: https://crisprbits.com/

Cover Block

Metric Value
Name CrisprBits
Tagline Developing affordable CRISPR-based diagnostics, gene-editing tools, and therapeutics for human and planetary well-being.
Headquarters Bengaluru, India
Founded 2020
Business Model B2B
Industry Healthtech
Technology Biotech / Life Sciences
Geography South Asia
Growth Profile Venture Scale
Founding Team Co-Founders (3+)
Funding Label Seed (total disclosed ~$3,250,000)

Links

What an Investor Needs First

CrisprBits is an early-stage Indian biotech company applying CRISPR gene-editing to build a multi-platform business across diagnostics, industrial tools, and future therapeutics. Founded in 2020 by five alumni of BITS Pilani, the company has progressed from incubation to a $3 million pre-Series A round [Inc42] [Indian Startup Times, 2025]. Its core commercial effort is PathCrisp, a point-of-need molecular diagnostics platform targeting diseases like sickle cell and typhoid [PERPLEXITY SONAR PRO BRIEF].

The company's business model is B2B, targeting hospitals, diagnostic labs, and industrial partners. The recent funding, led by Spectrum Impact with participation from HBL Engineering and C-CAMP, is earmarked for scaling manufacturing and commercialization of PathCrisp [Inc42].

Data Accuracy: YELLOW -- Core company facts and recent funding are confirmed by multiple sources; specific founder roles and detailed commercial metrics are less corroborated.

Taxonomy Snapshot

Axis Value
Business Model B2B
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography South Asia
Growth Profile Venture Scale
Founding Team Co-Founders (3+)
Funding Seed (total disclosed ~$3,250,000)

Inside the Company

CrisprBits was founded in 2020 by a group of five alumni from BITS Pilani. The company is headquartered in Bengaluru, India, and has operated from a 7,300-square-foot R&D and prototype development facility in the city since its inception [PERPLEXITY SONAR PRO BRIEF]. Its early development was supported by incubation at the Centre for Cellular and Molecular Platforms (C-CAMP) [PERPLEXITY SONAR PRO BRIEF] [Inc42].

In November 2025, the company closed its first publicly disclosed funding round, a $3 million pre-Series A led by Spectrum Impact with participation from the promoter family of HBL Engineering and C-CAMP [Inc42] [Indian Startup Times, 2025]. This capital was earmarked to scale commercialization of its flagship PathCrisp diagnostic platform and expand manufacturing capacity [PERPLEXITY SONAR PRO BRIEF]. The round reportedly valued the company at $12 million post-money [Indian Startup Times, 2025].

Data Accuracy: GREEN -- Company founding, headquarters, and incubation corroborated by multiple sources; funding round details and valuation confirmed by independent business publications.

Under the Hood

CrisprBits operates as a platform-first biotech company, organizing its CRISPR-based technology into three distinct but related product pillars [PERPLEXITY SONAR PRO BRIEF].

The flagship product is the PathCrisp platform, a molecular diagnostic system designed for rapid, point-of-need testing. The company is developing specific tests for sickle cell disease, typhoid, and antimicrobial resistance [PERPLEXITY SONAR PRO BRIEF]. A key public milestone is a partnership with Molbio Diagnostics to develop and distribute CRISPR-based point-of-care tests [Digital Health News].

The second pillar, EdiCrisp, applies CRISPR gene-editing tools to industrial processes, with biofuel production cited as a starting application [Express Healthcare]. The third pillar is CurieCrisp, a platform for curing genetic disorders through therapeutic gene-editing [PERPLEXITY SONAR PRO BRIEF].

Data Accuracy: GREEN -- Product descriptions and platform strategy are consistently reported across multiple industry publications and company statements.

Market Research

Market Segment Cited Size / Growth
Global Point-of-Care Diagnostics ~$40B (2023), ~9% CAGR
Indian Diagnostics Market >$10B
Target Conditions National Sickle Cell Anaemia Elimination Mission launched

Data Accuracy: YELLOW -- Market sizing relies on analogous, broad industry reports. Specific TAM/SAM for CRISPR diagnostics in LMICs is not corroborated by public third-party analysis.

Competition and Substitutes

Company Positioning Stage / Funding Notable Differentiator
CrisprBits Platform-first biotech with CRISPR-based diagnostics (PathCrisp), industrial gene editing (EdiCrisp), and future therapeutics (CurieCrisp). Pre-Series A, ~$3.25M total disclosed. Post-money valuation $12M (Nov 2025). Focus on low-cost, point-of-need diagnostics for India and emerging markets.

Data Accuracy: YELLOW -- Competitor details are sparse and based on limited public profiles; the Molbio partnership is confirmed, but other competitive dynamics are inferred from market context.

Opportunity

The headline opportunity is to become the de facto standard for point-of-care molecular diagnostics in emerging economies, starting with India. The recent $3 million pre-Series A round is earmarked specifically to scale the commercialization and manufacturing of this platform [Inc42].

Data Accuracy: YELLOW -- The core opportunity thesis is built from company statements and media reports detailing product focus and expansion plans.

Sources

Articles about CrisprBits

Related companies

Topics

View on Startuply.vc